A stark divergence in pharmaceutical access has emerged between Canada and the United States, raising questions about market incentives, regulatory frameworks, and public health priorities. While Canadian patients can purchase generic versions of semaglutide, the active ingredient in the blockbuster diabetes drug Ozempic, their American counterparts remain restricted to the branded, patent-protected product. This discrepancy is not an anomaly but a symptom of deeper structural differences in how the two countries approach drug pricing and availability.
The key factor lies in Canada’s Patented Medicine Prices Review Board, which caps the cost of patented drugs. Because Canadian law allows generic manufacturers to enter the market earlier under certain conditions, competition has driven down prices. In contrast, the US system relies on patent exclusivity and market-based pricing, with limited government intervention. As a result, Ozempic’s manufacturer, Novo Nordisk, faces no generic competition in the United States, where the list price for a month’s supply hovers around $900. In Canada, generic semaglutide costs roughly $150 per month.
This price gap has direct consequences for patients and public health systems. In Canada, broader access to cheaper generics has improved diabetes management rates and reduced the burden on provincial healthcare budgets. In the United States, high costs have led to rationing, with some patients skipping doses or turning to less effective alternatives. The disparity also highlights the influence of lobbying and intellectual property law. US lawmakers have struggled to pass legislation that would allow Medicare to negotiate drug prices, a power that Canadian provinces already exercise.
Proposed solutions in the US include allowing importation from Canada and reforming patent laws to shorten exclusivity periods. However, pharmaceutical companies argue that high prices fund research and development. This debate has intensified following reports of supply shortages and profit margins exceeding 50 per cent for certain drugs.
The implications extend beyond semaglutide. This case serves as a microcosm of a broader public health divide. As diabetes prevalence rises in both countries, the question remains: can the US afford to rely on market forces alone, or must it adopt some form of price regulation? For now, Canadians enjoy a competitive market that delivers affordable medicine. Americans are left waiting for a fix that, like the drugs themselves, may come at a premium.
